Cancers,
Год журнала:
2022,
Номер
14(4), С. 1028 - 1028
Опубликована: Фев. 17, 2022
Though
early-stage
colorectal
cancer
has
a
high
5
year
survival
rate
of
65–92%
depending
on
the
specific
stage,
this
probability
drops
to
13%
after
metastasizes.
Frontline
treatments
for
such
as
chemotherapy
and
radiation
often
produce
dose-limiting
toxicities
in
patients
acquired
resistance
cells.
Additional
targeted
are
needed
improve
patient
outcomes
quality
life.
Immunotherapy
involves
treatment
with
peptides,
cells,
antibodies,
viruses,
or
small
molecules
engage
train
immune
system
kill
Preclinical
clinical
investigations
immunotherapy
including
checkpoint
blockade,
adoptive
cell
therapy,
monoclonal
oncolytic
anti-cancer
vaccines,
modulators
have
been
promising,
but
demonstrate
limitations
proficient
mismatch
repair
enzymes.
In
review,
we
discuss
preclinical
studies
investigating
predictive
biomarkers
response
these
treatments.
We
also
consider
open
questions
optimal
combination
maximize
efficacy,
minimize
toxicity,
prevent
approaches
sensitize
repair-proficient
immunotherapy.
International Journal of Molecular Sciences,
Год журнала:
2019,
Номер
20(8), С. 1877 - 1877
Опубликована: Апрель 16, 2019
The
transient
receptor
potential
melastatin-subfamily
member
7
(TRPM7)
is
a
ubiquitously
expressed
chanzyme
that
possesses
an
ion
channel
permeable
to
the
divalent
cations
Mg2+,
Ca2+,
and
Zn2+,
α-kinase
phosphorylates
downstream
substrates.
TRPM7
its
homologue
TRPM6
have
been
implicated
in
variety
of
cellular
functions
critically
associated
with
intracellular
signaling,
including
tyrosine
kinase
(RTK)-mediated
pathways.
Emerging
evidence
indicates
growth
factors,
such
as
EGF
VEGF,
signal
through
their
RTKs,
which
regulate
activity
TRPM7.
primarily
epithelial-associated
channel,
while
more
ubiquitous.
In
this
review
we
focus
on
association
signaling.
We
also
highlight
how
interplay
between
TRPM7,
Mg2+
signaling
kinases
influences
cell
function
physiological
pathological
conditions,
cancer
preeclampsia.
Current Oncology,
Год журнала:
2011,
Номер
18(3), С. 126 - 138
Опубликована: Июнь 1, 2011
Non-small-cell
lung
cancer
(nsclc)
has
the
highest
prevalence
of
all
types
cancer,
which
is
second
most
common
and
leading
cause
cancer-related
mortality
in
Canada.
The
need
for
more
effective
less
toxic
treatment
options
nsclc
led
to
development
agents
targeting
epidermal
growth
factor
receptor
(egfr)–mediated
signalling
pathway,
such
as
egfr
tyrosine
kinase
inhibitors
(egfr-tkis).
Although
egfr-tkis
are
than
traditional
anti-neoplastic
agents,
they
commonly
associated
with
acneiform-like
rash
diarrhea.
This
review
summarizes
clinical
presentation
causes
egfr-tki–induced
diarrhea,
presents
strategies
assessment,
monitoring,
these
adverse
effects.
Strategies
improve
management
egfr-tki–related
events
should
outcomes,
compliance,
quality
life
patients
advanced
nsclc.
Cancer Treatment Reviews,
Год журнала:
2017,
Номер
62, С. 39 - 49
Опубликована: Окт. 23, 2017
Non-small
cell
lung
cancer
(NSCLC)
is
one
of
the
most
prevalent
cancers
and
responsible
for
a
large
proportion
all
cancer-related
deaths.
Current
treatment
options
are
inadequate,
reflecting
substantial
unmet
clinical
need.
Increasing
knowledge
regarding
mechanisms
genetic
aberrations
underlying
tumor
development
growth
has
heralded
new
era
therapy
in
oncology,
moving
away
from
indiscriminate
cytotoxic
chemotherapy
toward
more
finely
focused,
targeted
medicine.
The
small-molecule
drugs
monoclonal
antibodies
directed
specific
components
dysfunctional
molecular
or
immune
pathways,
mutated
genes
to
particular
types,
leading
field
personalized
less
toxic
options,
many
which
have
demonstrated
greater
efficacy
survival
benefits
than
their
chemotherapeutic
counterparts.
Particularly
successful
examples
agents
that
interfere
with
programmed
death
1
(PD-1)
pathway,
tumors
can
hijack
avoid
surveillance
editing.
Pembrolizumab,
antibody
at
PD-1
blocks
engagement
between
its
ligands,
been
explored
as
solid
tumors,
several
studies.
use
inhibitors
such
nivolumab
pembrolizumab
advanced
widespread,
available
60
countries
least
following:
melanoma,
PD-L1-expressing
NSCLC,
head
neck
squamous
carcinoma,
adult
pediatric
patients
refractory
classical
Hodgkin's
lymphoma.
This
work
provides
brief
overview
role
(recurrent/metastatic)
NSCLC.
Cancer Chemotherapy and Pharmacology,
Год журнала:
2017,
Номер
80(6), С. 1209 - 1217
Опубликована: Окт. 26, 2017
Patients
with
recurrent
glioblastoma
(rGBM)
have
a
poor
prognosis.
Epidermal
growth
factor
receptor
(EGFR)
gene
amplification
is
present
in
~
50%
of
glioblastomas
(GBMs).
Depatuxizumab
mafodotin
(depatux-m),
formerly
ABT-414,
an
antibody-drug
conjugate
that
preferentially
binds
cells
EGFR
amplification,
internalized
and
releases
potent
antimicrotubule
agent,
monomethyl
auristatin
F
(MMAF).
Here
we
report
the
safety,
pharmacokinetics,
efficacy
depatux-m
monotherapy
at
recommended
Phase
2
dose
(RPTD)
patients
EGFR-amplified,
rGBM.
Molecular & Cellular Oncology,
Год журнала:
2015,
Номер
2(4), С. e1004969 - e1004969
Опубликована: Июнь 1, 2015
The
epidermal
growth
factor
receptor
(EGFR)
is
a
tyrosine
kinase
that
frequently
mutated
or
overexpressed
in
large
number
of
tumors
such
as
carcinomas
glioblastoma.
Inhibitors
EGFR
activation
have
been
successfully
established
for
the
therapy
some
cancers
and
are
more
being
used
first
later
line
therapies.
Although
side
effects
induced
by
inhibitors
less
severe
than
those
observed
with
classic
cytotoxic
chemotherapy
can
usually
be
handled
out-patient
care,
they
may
still
cause
dose
reduction
discontinuation
treatment
reduce
effectiveness
antitumor
therapy.
mechanisms
underlying
these
cutaneous
only
partly
understood.
Important
questions,
reasons
correlation
between
intensity
efficiency
inhibitors,
remain
to
answered.
Optimized
adjuvant
strategies
accompany
anti-EGFR
need
found
optimal
therapeutic
application
improved
quality
life
patients.
Here,
we
summarize
current
literature
on
molecular
cellular
provide
evidence
keratinocytes
probably
targets
aimed
at
alleviating
skin
toxicities.
